Point72 Asset Management, L.P.

Position in JANX — Janux Therapeutics, Inc.

CIK 1603466 STAMFORD, CT

Position in JANX

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$16,070,346

+$2,797,244 QoQ

Shares Held

1,156,140

+20.2% QoQ

Ownership

1.90%

of shares outstanding

% of Portfolio

0.03%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2024

8 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Healthcare · as of Mar 31, 2026

Point72 Asset Management, L.P. holds $2,393,450,612 across 188 Biotechnology names. JANX ranks #42 (0.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	APLS	Apellis Pharmaceuticals, Inc.	4,183,918	$168,319,021
2	MDGL	Madrigal Pharmaceuticals, Inc.	225,510	$118,047,719
3	CLDX	Celldex Therapeutics, Inc.	3,229,939	$102,453,665
4	RYTM	Rhythm Pharmaceuticals, Inc.	846,801	$73,646,282
5	AXSM	Axsome Therapeutics, Inc.	424,750	$71,791,245
6	ABVX	Abivax S.A.	637,736	$71,011,903
7	LEGN	Legend Biotech Corp	3,886,017	$70,298,047
8	JAZZ	Jazz Pharmaceuticals plc	358,634	$67,799,757

9 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-04-28	$44,511,505	3,069,759	+165.5%	Shares	Sole	2026-04-29
2026-03-31	$16,070,346	1,156,140	+20.2%	Shares	Defined	2026-05-15
2025-12-31	$13,273,102	961,819	-43.8%	Shares	Defined	2026-02-17
2025-09-30	$41,797,288	1,710,200	-20.2%	Shares	Defined	2025-11-14
2025-06-30	$49,524,090	2,143,900	+469.2%	Shares	Defined	2025-08-14
2025-03-31	$10,169,874	376,662	-39.4%	Shares	Defined	2025-07-21
2024-12-31	$33,268,845	621,383	+57.0%	Shares	Defined	2025-02-14
2024-09-30	$17,984,601	395,875	+190.2%	Shares	Defined	2024-11-14
2024-06-30	$5,715,052	136,430	—	Shares	Defined	2024-09-16
No filing history on record for this holder in this stock.